Results 141 to 150 of about 79,317 (281)

Quantitative Systems Pharmacology Modeling of Platelet Responses to Recombinant ADAMTS13 in Patients With Congenital Thrombotic Thrombocytopenic Purpura. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Congenital thrombotic thrombocytopenic purpura (cTTP) is an ultra‐rare, life‐threatening thrombotic microangiopathy caused by a severe inherited deficiency of ADAMTS13, a von Willebrand factor (VWF) cleaving enzyme. Inadequate clinical endpoint data often make it challenging to statistically power clinical trials in ultra‐rare diseases ...
McBride C, Jiang J, Zhang Z, Tolsma J, Patwari P, Mellgård B, Vakilynejad M, Bhattacharya I, Zhu AZX.   +8 more
europepmc   +2 more sources

Factor VIII/von willebrand factor (FVIII/vWF) in a new intermediate factor VIII concentrate, RCG-5 Japan Red Cross.

, 1985
Akira Yoshioka, Masato Nishino, Midori Shima, Noboru Yoshikawa, Motoshi Yasui, Hiromu Fukui   +5 more
openalex   +2 more sources

Determining the Impact of Combination Oral Contraceptives on Von Willebrand Factor and Factor VIII in Healthy Patients and Patients With Von Willebrand Disease: A Scoping Review and Meta‐Analysis

Haemophilia, EarlyView.
ABSTRACT Introduction Von Willebrand disease (VWD) is a bleeding disorder characterized by a deficiency or dysfunction of Von Willebrand factor (VWF) and/or Factor VIII (FVIII), critical coagulation proteins. Individuals with VWD often use combination oral contraceptives (COCs) to manage heavy menstrual bleeding.
Eve Justason, Anna M. Ishchuk, Benjamin P. Ott, M. E. Sophie Gibson, Paula D. James   +4 more
wiley   +1 more source

Prevalence and Impact of Heavy Menstrual Bleeding in Women With von Willebrand Disease Across Age Groups: A Retrospective Study

Haemophilia, EarlyView.
ABSTRACT Introduction Heavy menstrual bleeding (HMB) is a common and burdensome symptom in women with von Willebrand disease (VWD). Although VWD and HMB have been studied, the prevalence and impact of HMB across different age groups remains underexplored. Aim To investigate the prevalence and impact of HMB in women with VWD across different age groups.
Anna Olsson, Petra Elfvinge, Eva Zetterberg, Linda Myrin‐Westesson   +3 more
wiley   +1 more source

ADAMTS‐13 activity in plasma is rapidly measured by a new ELISA method that uses recombinant VWF‐A2 domain as substrate [PDF]

, 2004
Jody L. Whitelock, Leticia Nolasco, A. Bernardo, Joel L. Moake, J‐F. Dong, Miguel A. Crúz   +5 more
openalex   +1 more source

Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing Study

Haemophilia, EarlyView.
ABSTRACT Introduction Although clinical experience of a triple‐secured, plasma‐derived, von Willebrand factor (pdVWF), almost devoid of Factor VIII (FVIII) in adults with von Willebrand disease (VWD), is widely reported, its use in children is less documented.
Jenny Goudemand, Annie Borel‐Derlon, Ségolène Claeyssens, Hervé Chambost, Guillaume Mourey, Annie Harroche, Sandrine Meunier, Céline Henriet, Thierry Leroi, Sophie Susen, Yohann Repesse   +10 more
wiley   +1 more source

C1qTNF–related protein-1 (CTRP-1): a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking VWF binding to collagen [PDF]

, 2005
Gerald Lasser, Prasenjit Guchhait, Jeff L. Ellsworth, Paul O. Sheppard, Ken Lewis, Paul D. Bishop, Miguel A. Crúz, José A. López, Joachim Fruebis   +8 more
openalex   +1 more source

The Mirage of Factor Equivalence: Examining the Complexities of Non‐Factor Therapies in Haemophilia

Haemophilia, EarlyView.
ABSTRACT Background This article provides a critical analysis of the ‘factor equivalence’ concept as applied to non‐factor therapies (NFTs) for haemophilia, highlighting its limitations and clinical implications. Although factor equivalence estimates serve as a comparative tool for evaluating pro‐coagulant effects across different therapies, they may ...
Yesim Dargaud, Arianna Colombo, Maria Elisa Mancuso   +2 more
wiley   +1 more source

The role of platelet membrane proteins in the interaction of platelet-vWF-collagen.

, 1988
Morio Aihara, Yoshihiro Tamura, IKUO KUDO, Yoshihiko Sawada, Masaki Munakata, N Moriya, Shigeo Morimoto, Yutaka Yoshida   +7 more
openalex   +2 more sources

A critical role for 14-3-3ζ protein in regulating the VWF binding function of platelet glycoprotein Ib-IX and its therapeutic implications [PDF]

, 2005
Kesheng Dai, Richard J. Bodnar, Michael C. Berndt, Xiaoping Du   +3 more
openalex   +1 more source